Rencontrez-nous à…
Toute l’actualité d’OTR3
News
OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on Post-surgical Scars
Media Publications
Isabelle Barbosa, Christophe Morin, Stephanie Garcia, Arlette Duchesnay, Mustapha Oudghir, Guido Jenniskens, Hua-Quan Miao, Scott Guimond, Gilles Carpentier, José Cebrian, Jean-Pierre Caruelle, Toin van Kuppevelt, Jeremy Turnbull, Isabelle Martelly, Dulce Papy-Garcia Abstract Crucial events in myogenesis rely on the highly regulated spatiotemporal distribution of cell surface heparan sulfate proteoglycans to [...]
Cacipliq 20
Cacipliq 20® - Foot Ulcer Efficacy of a New Heparan Sulfate Mimetic Dressing in the Healing of Foot and Lower Extremity Ulcerations in Type 2 Diabetes: A Case Series Nikolaos Papanas, Costas Demetzos, Natassa Pippa, Efstratios Maltezos and Nicholas Tentolouris A novel heparan sulfate glycosaminoglycan mimetic product for local [...]
Cacipliq 20
Cacipliq 20® - hand injury ReGeneraTing Agents (RGTA®) are a new option to improve amputation outcomes in the recovery of severe hand injuries Roohi Sharifah Ahmad and Denis Barritault Cacipliq 20® was used to accelerate the healing process and stimulate the viability of flaps and skin grafts, thereby improving [...]
